AHFS Drug Information®

Trusted by pharmacists and other healthcare professionals for over 60 years, the AHFS Drug Information® Database is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

AHFS is the only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization and the only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.

Updates Include: 

  • Approximately 1,700 monographs incorporating over 94,000 references covering information on indications, dosage and administration, contraindications, warnings and precautions, adverse effects, drug interactions, pharmacology, pharmacokinetics, and more
  • Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
  • The latest information on the changing landscape of predominant COVID-19 subvariants and its effects on COVID therapeutics, including updated 2023-2024 mRNA vaccine formulations, changes in emergency use authorization (EUA) status, and updated recommendations from the Infectious Diseases Society of America (IDSA), and the National Institutes of Health (NIH)
  • Contemporary topics such as new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
  • Inclusion of Standardize4Safety concentration standards for IV and oral liquid drugs
  • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
  • Expanded content on off-label uses, real-word data, and long-term clinical data
  • Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
  • New content on gene therapies for the treatment of cancers and certain inherited disorders
  • The latest information from FDA safety communications regarding opioid pain medications ,stimulant drugs, ketamine, and BCMA- or CD19-directed autologous CAR T cell immunotherapies
  • Addition of 175 new molecular entities (NMEs) and new therapeutic biological products approved since Jan 2023

AHFS Drug Information® Database is easily integrated directly into your website or software application and

  • Updated monthly
  • Available in XML
ASHP Licensing

AHFS DI® Essentials™

AHFS DI® Essentials™ Database builds on the foundation of AHFS Drug Information® by providing a resource that focuses on the essential evidence-based information that allows pharmacists, nurses, physicians, and other healthcare providers to quickly access the specific guidance needed to safely and effectively monitor and prescribe drug therapy. Because it is derived from the authoritative AHFS Drug Information®, the well-respected information development process, evidence analysis, and expert advice of authoritative reviewers are encapsulated and summarized in the format of Essentials.

AHFS DI® Essentials™ is designed to offer health-care clinicians easy access to knowledge that is critical at the point of care. Essentials monographs draw on the meticulously developed evidence-based guidelines in the full AHFS DI database, distilling for the health-care professional the essential information on prescription and key over-the-counter (OTC) drugs in an easy-to-use, highly structured outline format.

Updates include:

  • Content not found in the full AHFS DI® Database: compatibility and drug interactions tables.
  • Monographs include: drug interactions; adverse reactions; cautions and toxicity; therapeutic perspective; specific dosage and administration information; preparations, stability and storage information; pharmacology and pharmacokinetics; contraindications; and more.
  • Current drug shortage information

AHFS DI® Essentials™ Database is

  • Updated monthly
  • Available in XML

Download a Sample Monograph


Case Studies

InpharmD case study imageInpharmD™

Reliable, evidence-based drug information conferred by pharmacists and communicated via artificial intelligence backed by data from AHFS Drug Information.

Read More >>

ADVERTISEMENT

Contact Us 

If you are interested in learning more about our ASHP and AHFS Drug Databases, please complete the Contact Us form and an ASHP representative will be in contact.

Contact Us